In this episode of Better Edge, Joshua Meeks, MD, PhD, discusses the implications of the FDA's recent approval of TAR-200, a novel therapy for bladder cancer. Having played a key role in the clinical trials and development of this treatment, Dr. Meeks provides an in-depth look at this breakthrough’s potential to transform patient care, especially for those with BCG-unresponsive bladder cancer.